罗氏(RHHBY.US)4亿美元加码IBD领域开发临床前口服小分子

智通财经09-02

智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团(RHHBY.US)成员基因泰克(Genentech)达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病(IBD)的临床前口服小分子项目。OMass是一家针对膜蛋白或细胞内复合物等经过高度验证的靶点生态系统开发药物的生物技术公司。根据协议条款，OMass将获得2000万美元的首付款，此外还有...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2564007528?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-02 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564007528","market":"hk","top_or_hot":-1,"title":"罗氏(RHHBY.US)4亿美元加码IBD领域 开发临床前口服小分子","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团(RHHBY.US)成员基因泰克(Genentech)达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病(IBD)的临床前口服小分子项目。OMass是一家针对膜蛋白或细胞内复合物等经过高度验证的靶点生态系统开发药物的生物技术公司。根据协议条款，OMass将获得2000万美元的首付款，此外还有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1340712.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏(RHHBY.US)4亿美元加码IBD领域 开发临床前口服小分子</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏(RHHBY.US)4亿美元加码IBD领域 开发临床前口服小分子\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-02 21:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1340712.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团(RHHBY.US)成员基因泰克(Genentech)达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病(IBD)的临床前口服小分子项目。OMass是一家针对膜蛋白或细胞内复合物等经过高度验证的靶点生态系统开发药物的生物技术公司。根据协议条款，OMass将获得2000万美元的首付款，此外还有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1340712.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1340712.html","article_id":"2564007528","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564007528","pubTimestamp":1756818907,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团成员基因泰克达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病的临床前口服小分子项目。根据协议条款，OMass将获得2000万美元的首付款，此外还有可能获得超过4亿美元的潜在临床前、开发、商业和净销售额里程碑付款。在此合作下，OMass将主导该项目的初步临床前开发，直至候选化合物选定。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03165":"华夏欧优股对冲","RHHBY":"罗氏控股","IBD":"Inspire Corporate Bond ETF","BK4007":"制药"},"translate_title":"Roche (RHHBY.US) invests US $400 million in the IBD field to develop preclinical oral small molecules","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBD":1,"03165":0.6,"RHHBY":1},"content_text":"智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团(RHHBY.US)成员基因泰克(Genentech)达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病(IBD)的临床前口服小分子项目。OMass是一家针对膜蛋白或细胞内复合物等经过高度验证的靶点生态系统开发药物的生物技术公司。根据协议条款，OMass将获得2000万美元的首付款，此外还有可能获得超过4亿美元的潜在临床前、开发、商业和净销售额里程碑付款。OMass也有资格根据净销售额获得分层特许权使用费。在此合作下，OMass将主导该项目的初步临床前开发，直至候选化合物选定。基因泰克将负责临床开发、注册申报、生产及商业化活动。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564007528","isCrawlerRequest":true}

罗氏(RHHBY.US)4亿美元加码IBD领域 开发临床前口服小分子

精彩评论

罗氏(RHHBY.US)4亿美元加码IBD领域开发临床前口服小分子